01—Abstract
Summary
Summary of the 8-K filed May 27, 2025. Cited figures are marked; the original filing is the authoritative source.
Amgen Inc. (AMGN) filed an 8-K report on May 27, 2025, detailing the outcomes of its annual meeting of stockholders held on May 22, 2025.
The report primarily covers the election of directors, advisory votes on executive compensation, and the ratification of independent auditors. All 12 director nominees were overwhelmingly elected to serve a one-year term. Additionally, shareholders provided an advisory vote to approve executive compensation, which passed with a significant majority.
Furthermore, the company's selection of Ernst & Young LLP as its independent registered public accountants for the fiscal year ending December 31, 2025, was ratified by stockholders. The voting results across all presented proposals indicate strong shareholder support for the company's governance and financial oversight practices. No other business was presented or voted upon during the meeting.
02—Key points
Key Highlights
- All 12 director nominees were elected to serve a one-year term until the 2026 annual meeting.
- The advisory vote to approve executive compensation received strong majority support from shareholders.
- Ernst & Young LLP was ratified as Amgen's independent registered public accountants for the fiscal year ending December 31, 2025.
- Voting outcomes for director elections showed overwhelming support, with 'Votes For' significantly outnumbering 'Votes Against' and 'Abstain' for all nominees.
- Broker non-votes were present in the director election and executive compensation vote, a common occurrence in publicly traded companies.
- No other business matters were submitted for stockholder action at the meeting.
03—Questions
Frequently Asked Questions
What were the key outcomes of Amgen's annual shareholder meeting?
The key outcomes include the election of all 12 director nominees, an advisory approval of the company's executive compensation, and the ratification of Ernst & Young LLP as the independent registered public accountants for fiscal year 2025. All proposals received substantial shareholder support.
How did shareholders vote on executive compensation?
Shareholders provided an advisory vote to approve executive compensation. The proposal passed with a significant majority, with 381,269,281 votes in favor, 21,382,050 votes against, and 1,909,343 abstentions.
Who will serve as Amgen's auditors for 2025?
Ernst & Young LLP has been ratified by shareholders to serve as Amgen's independent registered public accountants for the fiscal year ending December 31, 2025.
Were there any contested director seats or significant opposition to the board's nominees?
No, all 12 director nominees were overwhelmingly elected. The 'Votes For' significantly exceeded 'Votes Against' and 'Abstain' for every nominee, indicating strong shareholder confidence in the current board composition.
04—Continue